Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Acute Undifferentiated Leukemia

Children's Oncology Groupprotein_peptidePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Acute Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
DEXAMETHASONE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB

View all 50 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →